[
    [
        {
            "time": "2018-01-02",
            "original_text": "A Look at Vanda Pharmaceuticals’ Product Portfolio",
            "features": {
                "keywords": [
                    "Vanda Pharmaceuticals",
                    "Product Portfolio"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "A Look at Vanda Pharmaceuticals’ Product Portfolio",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Endo, Glaxo to Settle Suits Over Testosterone Drug",
            "features": {
                "keywords": [
                    "Endo",
                    "Glaxo",
                    "Settle",
                    "Suits",
                    "Testosterone Drug"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Endo, Glaxo to Settle Suits Over Testosterone Drug",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Analysts’ Post-4Q17 Recommendations for Eli Lilly",
            "features": {
                "keywords": [
                    "Analysts",
                    "Recommendations",
                    "Eli Lilly",
                    "4Q17"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Analysts’ Post-4Q17 Recommendations for Eli Lilly",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Comparing Eli Lilly’s Post-4Q17 Valuation",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Valuation",
                    "4Q17"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Comparing Eli Lilly’s Post-4Q17 Valuation",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Today’s Research Reports on Trending Tickers: InspireMD and Eli Lilly and Company",
            "features": {
                "keywords": [
                    "Research Reports",
                    "Trending Tickers",
                    "InspireMD",
                    "Eli Lilly"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "medical devices"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Today’s Research Reports on Trending Tickers: InspireMD and Eli Lilly and Company",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "How Eli Lilly’s Animal Health Segment Performed in 4Q17",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Animal Health",
                    "Segment",
                    "4Q17"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "animal health",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "How Eli Lilly’s Animal Health Segment Performed in 4Q17",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]